Nick George has been developing and evaluating biologics-based patent portfolios for more than 20 years. He has devised worldwide patent prosecution strategies and evaluated portfolios involving antibodies, antibody drug conjugates, immuno-oncology, cellular therapeutics (including stem cell, natural killer cell, CAR-T, and induced pluripotent stem cell (iPS) therapeutics), antisense and other RNA therapeutics, peptide therapeutics, CRISPR technologies, companion diagnostics, enzyme replacements, and gene therapy, among others.
Nick has developed patent strategies for such marketed products as Fuzeon®, Kynamro®, Fabrazyme®, Syvek®, and Talymed® and for such drug candidates as Celgene and Celularity's cellular therapeutics, Celldex Therapeutics' ErbB3 and KIT antibody clinical candidates, and Kyowa Hakko Kirin's LIGHT antibody portfolio, subsequently licensed to Sanofi in a deal valued at $300+ million. He also has developed patent strategies for such diagnostic products as Phenosense™, GeneSeq™, Replication Capacity™, and the companion diagnostic, Trofile™ (Monogram, now LabCorp).
Nick holds a Ph.D. in genetics from the University of California, Berkeley (1990). Following a postdoctoral fellowship at Columbia University, he joined the legal intern program at his previous firm, during which time he also attended the evening program of Fordham University Law School.
- Fordham University (J.D. 1997); Columbia University (Postdoctoral Fellow, 1990-1992); University of California, Berkeley (Ph.D. in Genetics 1990); University of Dallas (B.S. in Biology cum laude 1984)
- New York and registered to practice before the United States Patent and Trademark Office